News
During a Q2 earnings call, the firm discussed progress on an FGFR2b antibody, a subcutaneous version of Blincyto, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback